REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024PRNewsWire • Monday
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual MeetingPRNewsWire • 10/18/24
Goldman Sachs Recommends These 3 Growth Stocks As Strong Buys in September24/7 Wall Street • 09/09/24
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic EffectPRNewsWire • 09/03/24
REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumPRNewsWire • 08/27/24
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferencePRNewsWire • 08/08/24
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a BetZacks Investment Research • 08/06/24
REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational HighlightsPRNewsWire • 08/01/24
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational HighlightsPRNewsWire • 07/25/24
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?Zacks Investment Research • 07/12/24
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/25/24
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger PatientsPRNewsWire • 06/24/24
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS IIPRNewsWire • 06/18/24
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong BuySeeking Alpha • 06/11/24
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferencePRNewsWire • 06/05/24